StockNews.com Begins Coverage on Oncternal Therapeutics (NASDAQ:ONCT)

Analysts at StockNews.com started coverage on shares of Oncternal Therapeutics (NASDAQ:ONCT) in a research note issued to investors on Wednesday. The brokerage set a “hold” rating on the stock.

Oncternal Therapeutics Price Performance

NASDAQ ONCT opened at $0.53 on Wednesday. Oncternal Therapeutics has a 12-month low of $0.53 and a 12-month high of $9.88. The company has a market capitalization of $1.56 million, a PE ratio of -0.05 and a beta of 1.18. The firm’s 50 day moving average is $0.53 and its 200-day moving average is $1.04.

About Oncternal Therapeutics

Oncternal Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial.